Inovio Pharmaceuticals, Inc.
INO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.00 | 0.01 | -0.00 |
| FCF Yield | -26,272.55% | -60,701.80% | -39.56% | -51,862.35% |
| EV / EBITDA | -2.88 | -0.00 | 0.23 | -6.29 |
| Quality | ||||
| ROIC | -58.91% | -40.07% | -25.35% | -31.80% |
| Gross Margin | 0.00% | 100.00% | -563.14% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.88 | 1.36 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.23% | -73.34% | -69.70% | -72.32% |
| Free Cash Flow Growth | 22.56% | -136,566.76% | 99.98% | -294,214.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.00 | 2.90 | 0.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -665.41 | 1,804.65 | 175.02 | -632.88 |